Phaseline

Targets › ITGAM

ITGAM (Integrin alpha-M): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 2, 1 Phase 1; Respiratory, Oncology; next expected readout Jul 2028.

Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. (UniProt, P11215)

Open in Phaseline: the race on ITGAM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PPD Development, LPparidiprubart
CD11b/CD18 integrin antagonist
ITGAMPhase 2Acute Respiratory Distress Syndrome (ARDS)Jul 2028
Fondazione Matilde Tettamanti Menotti De Marchi OnlusCARCIK CD123/33
CAR-T cell therapy targeting CD123 and CD33
IL3RA, ITGAMPhase 1AML (Acute Myeloid Leukemia)Oct 2028

Conditions

Acute Respiratory Distress Syndrome (ARDS) (2) AML (Acute Myeloid Leukemia) (1)

Modalities

antibody (1), small molecule (1)

Companies

PPD Development, LP (1) Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1)

Related targets

IL3RA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.